STEVEN PAUL was elected chairman of the Foundation for the National Institutes of Health.
Paul succeeds Charles Sanders, who has served as chairman since 1997 and will remain a member of the board. In addition, Thomas Insel and Paul Stoffels were elected as new board members.
Paul is president and CEO at Voyager Therapeutics, Inc., as well as a venture partner at Third Rock Ventures. Prior to Voyager, Paul was founding director of the Helen and Robert Appel Alzheimer’s Disease Research Institute, the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases and a DeWitt Senior Scholar and professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Paul also spent 17 years at Eli Lilly and Company, where he was president of the Lilly Research Laboratories. Prior to Eli Lilly, Paul served as scientific director of the National Institute of Mental Health.
Insel is the director of clinical neuroscience at Verily, an Alphabet company, formerly known as Google Life Sciences. Insel served as director of the National Institute of Mental Health from 2002 to 2015, overseeing advances in mental health, neuroscience, diagnostics and therapeutics.
Prior to his appointment at the NIMH, Insel was a professor in the Department of Psychiatry and director of the Center for Behavioral Neuroscience at Emory University School of Medicine. He also served as director of the Center for Autism Research and is a member of the scientific advisory board at the Autism Science Foundation.
Stoffels is chief scientific officer at Johnson & Johnson. As a member of the executive committee, Stoffels oversees internal research and development across three business sectors, pharmaceuticals, consumer and medical devices. He also oversees Johnson & Johnson’s Global Public Health unit.
